Understanding Intermediate Risk Prostate Cancer: A Guide for Indian Men

What is Intermediate Risk Prostate Cancer? Prostate cancer is a significant health concern for men worldwide, and India is no exception. While the mention of cancer can be frightening, understanding the different stages and risk levels is crucial for effective management and treatment. Intermediate risk prostate cancer is a category that falls between low-risk and high-risk cancers. It signifies that the cancer has certain characteristics that suggest it might grow and spread more quickly than low-risk cancer, but less aggressively than high-risk cancer. This article aims to provide a clear and practical understanding of intermediate risk prostate cancer, tailored for the Indian context, covering its definition, symptoms, diagnosis, treatment options, and the importance of regular check-ups. Understanding Prostate Cancer Risk Levels To better manage prostate cancer, doctors and researchers categorize it into different risk groups. These categories help in determining the most appropriate treatment plan. The main risk groups are: Low Risk: Cancers that are very early stage, have a low Gleason score, and low PSA levels. They are less likely to grow or spread. Intermediate Risk: Cancers that show signs of potentially growing or spreading more than low-risk cancers, but less than high-risk ones. High Risk: Cancers that are more aggressive, with higher Gleason scores and PSA levels, and a greater likelihood of spreading. What Qualifies as Intermediate Risk Prostate Cancer? Intermediate risk prostate cancer is typically identified based on several key factors that doctors assess: 1. Physical Examination and Imaging Often, intermediate risk prostate cancers have grown large enough to be felt by a doctor during a digital rectal examination (DRE) and can be detected on imaging tests like an MRI or ultrasound. 2. Prostate-Specific Antigen (PSA) Levels PSA is a protein produced by the prostate gland. Elevated levels in the blood can indicate prostate cancer or other prostate conditions. For intermediate risk prostate cancer, PSA levels are generally between 10 and 20 nanograms per milliliter (ng/mL) of blood. It's important to note that PSA levels can be influenced by various factors, and a single high reading doesn't automatically mean cancer. 3. Gleason Score and Grade Group The Gleason score is a grading system used to determine how aggressive prostate cancer cells appear under a microscope. It ranges from 2 to 10, with higher scores indicating more aggressive cancer. The Grade Group is a newer system that categorizes Gleason scores into five groups (Grade Group 1 to 5), with Grade Group 1 being the least aggressive and Grade Group 5 being the most aggressive. For intermediate risk prostate cancer, the Gleason score is typically 7. This can be broken down into: 3+4 = 7 (Grade Group 2): This is considered favorable intermediate risk. 4+3 = 7 (Grade Group 3): This is considered unfavorable intermediate risk. 4. Cancer Stage (TNM Scale) The TNM (Tumor, Node, Metastasis) staging system describes how far the cancer has spread. For intermediate risk prostate cancer, it often falls into stage cT2b or cT2c. This means the cancer is confined within the prostate gland but may involve more than half of one side or both sides of the prostate. Types of Intermediate Risk Prostate Cancer Doctors further classify intermediate risk prostate cancer into two subtypes to better guide treatment decisions: Favorable Intermediate Risk Prostate Cancer This type has a lower likelihood of spreading beyond the prostate gland. Key indicators include: Gleason score of 3+4 = 7 (Grade Group 2) PSA levels typically between 10 and 20 ng/mL Cancer confined to the prostate (stage cT2b or cT2c) Cancers in this category may sometimes be managed with active surveillance, especially if they are slow-growing. Unfavorable Intermediate Risk Prostate Cancer This type generally indicates a higher risk of the cancer spreading. Key indicators include: Gleason score of 4+3 = 7 (Grade Group 3) PSA levels typically between 10 and 20 ng/mL Cancer confined to the prostate (stage cT2b or cT2c) Unfavorable intermediate risk cancers often require more definitive treatment due to their higher potential for progression. Symptoms of Prostate Cancer In its early stages, prostate cancer often shows no symptoms. However, as the cancer grows or spreads, some men may experience: Difficulty starting urination A weak or interrupted flow of urine Frequent urination, especially at night Difficulty emptying the bladder completely Pain or burning during urination Blood in the urine or semen Pain in the back, hips, or pelvis that doesn’t go away Painful ejaculation It's crucial to remember that these symptoms can also be caused by other non-cancerous prostate conditions like benign prostatic hyperplasia (BPH) or prostatitis. Therefore, consulting a doctor for proper diagnosis is essential. Diagnosis of Intermediate Risk Prostate Cancer Diagnosing intermediate risk prostate cancer involves a combination of methods: Digital Rectal Examination (DRE): A doctor inserts a gloved finger into the rectum to feel the prostate for any abnormalities like lumps or hard spots. PSA Blood Test: Measures the level of PSA in the blood. Prostate Biopsy: If DRE or PSA levels suggest a problem, a biopsy is performed. Small samples of prostate tissue are taken using a needle and examined under a microscope to confirm cancer and determine its Gleason score and Grade Group. Imaging Tests: MRI scans can help visualize the prostate gland, assess the extent of the cancer, and guide biopsy procedures. Other imaging tests like CT scans or bone scans may be used to check if the cancer has spread to other parts of the body, though this is less

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.